Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inbakicept - ImmunityBio

Next Previous
Drug Profile

Inbakicept - ImmunityBio

Alternative Names: ALT 803; Anktiva; Fusion protein consisting of IL-15N72D and IL-15RaSu/FC; IL-15N72D/IL-15Ra-Fc; IL-15N72D:IL-15RaSu/Fc fusion complex; IL-15N72D:IL-15RαSu/Fc fusion protein complex; interleukin-15 (IL-15) superagonist complex; N-803; Nogapendekin alfa; Nogapendekin alfa inbakicept; Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803; VesAnktiva™

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altor BioScience Corporation; NantKwest
  • Developer AIDS Clinical Trials Group; Altor BioScience Corporation; ImmunityBio; Masonic Cancer Center; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Thai Red Cross AIDS Research Centre; University of Minnesota; University of South Carolina; Walter Reed Army Institute of Research
  • Class Antibacterials; Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bladder cancer
  • Phase III Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Cervical cancer; Colorectal cancer; Gastric cancer; Hereditary nonpolyposis colorectal cancer; HIV infections; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Phase I/II Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Triple negative breast cancer
  • Phase I HIV-1 infections
  • No development reported Bacterial infections; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 20 Mar 2024 Dana-Farber Cancer Institute and ImmunityBio plans a phase I trial for Ovarian cancer (Recurrent, Combination therapy, Second-line therapy or greater, In adults, In elderly) in USA (NCT06321484)
  • 12 Mar 2024 Dana-Farber Cancer Institute in collaboration with ImmunityBio plans a phase 0 trial in Urogenital cancer/Renal Cell Carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV, infusion) in April 2024 (NCT06318871)
  • 06 Mar 2024 Pharmacodynamics data from a preclinical studies in HIV infections released by ImmunityBio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top